EUVIMEDEUVIMED entdecken
Open Access

The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success

Peter Saltonstall, Heidi Ross, Paul T Kim

The Milbank Quarterly · 2024-03 · 102 (1) · 83-96

DOI: 10.1111/1468-0009.12680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Milbank Quarterly, online erschienen am 12.12.2023. Verfasst von Peter Saltonstall und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Organization for Rare Disorders. Hauptthemen laut MEDLINE: Orphan Drug Production, Drug Approval. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Policy Points The Orphan Drug Act (ODA) was the result of patient advocacy and by many measures has been strikingly successful. However, approximately 95% of the more than 7,000 known rare diseases still have no US Food and Drug Administration–approved treatment. The ODA's success led to sustained criticism of high drug prices, often for products that have orphan drug indications. Critics misconstrue the ODA's intent and propose reducing its incentives instead of pursuing policies focused on addressing broader prescription drug price challenges that exist in both the orphan and nonorphan drug market. Patients and their families will continue to defend the purpose and integrity of the ODA and to drive investments into rare disease research and clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionDrug ApprovalUnited StatesHumansRare DiseasesUnited States Food and Drug Administration

Stichwörter der Autor:innen

FDAorphan drugrare diseases

Autor:innen und Institutionen

  • National Organization for Rare Disorders.
  • Kendall Square Policy Strategies LLC.

Zitieren

APA

Saltonstall, P., Ross, H., & Kim, P. T. (2024). The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success. The Milbank Quarterly, 102(1), 83-96. https://doi.org/10.1111/1468-0009.12680

Vancouver

Saltonstall P, Ross H, Kim PT. The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success. The Milbank Quarterly. 2024;102(1):83-96. doi:10.1111/1468-0009.12680

BibTeX
@article{Saltonstall2024,
  author = {Saltonstall, Peter and Ross, Heidi and Kim, Paul T},
  title = {The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success},
  journal = {The Milbank Quarterly},
  year = {2024},
  volume = {102},
  number = {1},
  pages = {83--96},
  doi = {10.1111/1468-0009.12680}
}
Kostenlos starten →